Health Technology Clinical Committee
Date: May 16, 2014
Time: 8:00 am – 5:00 pm
Location: SeaTac Airport Conference Center
Adopted: July 11, 2014

Meeting materials and transcript are available on the HTA website at:

HTCC MINUTES

Members Present: C. Craig Blackmore, MD, MPH; Marie-Annette Brown, PhD, RN; Joann Elmore, MD MPH; Carson E. Odegaard, DC, MPH; Richard C. Phillips, MD, MS, MPH; Seth Schwartz, MD, MPH; Michelle Simon, PhD, ND; Michael Souter, MB, Ch-B, DA, Christopher Standaert, MD; Kevin Walsh, MD

HTCC FORMAL ACTION

1. Call to Order: Dr. Blackmore, Chair, called the meeting to order. Sufficient members were present to constitute a quorum.

2. March 21, 2014, Meeting Minutes: Chair referred members to the draft minutes. A typographical error was identified by a committee member. Staff was directed to correct the error. Motion to approve the corrected minutes and seconded, and adopted by the committee.

   Action: Ten committee members approved the March 21, 2014 meeting minutes.

3. Nonpharmacological Treatments for Treatment-resistant Depression Draft Findings & Decision: Chair referred members to the draft findings and decision and called for further discussion. Two comments were received on the draft decision. Committee discussed comments related to specific language changes in draft determination. No changes were made. Motion to approve was seconded. Committee approved.

   Action: Ten committee members approved the Nonpharmacological Treatments for Treatment-resistant Depression Findings & Decision document.

4. Facet Neurotomy Draft Findings & Decision: Chair referred members to the draft findings and decision and called for further discussion. Nine comments were received on the draft decision. All comments are published with the May 16, meeting materials. Committee discussion focused on comments concerning C2-3 neurotomy and available evidence. Committee determined to make no changes to determination. Motion to approved was seconded. Committee voted on question to approve resulting in 5-0, a nonconclusive vote. Committee resumed discussion. A motion to revote was seconded and committee approved determination without changes.

   Action: Ten committee members approved the Facet Neurotomy Findings & Decision document.
5. Proton Beam Therapy:

**Scheduled and Open Public Comments:** The Chair called for public comments. Open public comments were presented by:

- Shannon MacDonald, MD, Assistant Professor, Harvard Medical School Department of Radiation Oncology, Massachusetts General Hospital
- Ralph Ermoian, MD, Assistant Professor, Department of Radiation Oncology, University of Washington School of Medicine
- George E. Laramore, MD, PhD, Peter Wootton Professor of Radiation Oncology, University of Washington School of Medicine *
- Ramesh Rengan, MD, PhD, Associate Professor, Department of Radiation Oncology, University of Washington School of Medicine, Associate Member, Fred Hutchinson Cancer Research Center, Medical Director, SCCA Proton Therapy *

*Presented comments on behalf of the following:

  - Smith “Jim” Apisarnthanarax, MD, Associate Professor, Department of Radiation Oncology, University of Washington School of Medicine
  - Ed Kim, MD, Associate Professor, Department of Radiation Oncology, University of Washington School of Medicine
  - Wui-Jin Koh, MD, Professor Department of Radiation Oncology, University of Washington School of Medicine
  - Nina A. Mayr, MD, FASSTRO, FAAAS, Professor & Chair, Department of Radiation Oncology, University of Washington School of Medicine
  - Shilpen Patel, MD, FACRO, Associate Professor, University of Washington School of Medicine, Medical Director of the Clinical Outcomes Assessment Program/Foundation for Health Care Quality, Chief of Thoracic Radiation Oncology/Stereotactic Body Radiation Therapy Program Lead
  - Jason K. Rockhill, MD, PhD, Associate Professor, Departments of Radiation Oncology & Neurological Surgery University of Washington School of Medicine, Co-Director, Gamma Knife Center, Co-Director, UW Medicine Clinical Neuro Oncology, Associate Residency Program Director, Department of Radiation Oncology University of Washington School of Medicine
  - George Sandison, PhD, FCCPM, FAAPM, Professor & Director of Medical Physics, Department of Radiation Oncology, Adjunct Professor Department of Radiology
  - University of Washington School of Medicine
  - Jing Zeng, MD, Assistant Professor, Department of Radiation Oncology, University of Washington School of Medicine
- Eugene B. Hug, MD, Professor of Proton-Radiotherapy University of Zurich, Medical Director, ProCure Proton Therapy Centers, Chief Medical Officer, ProCure
- Robin Baird, ProCure patient
- Norman E. Hubbard, CEO Seattle Cancer Care Alliance
- Vivek Mehta, MD, Director, Center of Advanced Targeted Radiotherapies, Swedish Cancer Institute
- Don Denton, patient, submitted a letter

Presentation materials and conflict of interest forms are available with [May 16, meeting materials](#).
Agency Utilization and Outcomes:

Daniel Lessler, MD, MHA, Chief Medical Officer, WA Health Care Authority presented the state agency utilization rates for Proton Beam Therapy to the committee. The full presentation is published with May 16, meeting materials.

Vendor Report and HTCC Q & A:

The Chair introduced the clinical expert and explained the clinical expert’s role. Lia M Halasz, MD is the Assistant Professor, Department of Radiation Oncology and Joint Assistant Professor, Department of Neurological Surgery, University of Washington School of Medicine.

Daniel A. Ollendorf, MPH, of the Institute for Clinical and Economic Research (ICER), presented the evidence review addressing Proton Beam Therapy. The full presentation is published with May 16, meeting materials.

Committee Discussion and Decision:

The HTCC reviewed and considered the Proton Beam Therapy technology assessment report. They also heard comments from the evidence reviewer, the clinical expert, the public, and agency medical directors. The committee considered all the evidence and gave greatest weight to the evidence it determined, based on objective factors, to be the most valid and reliable. [See transcript for full committee deliberations.]

The HTCC Committee Coverage Determination Vote

<table>
<thead>
<tr>
<th>HTCC Committee Coverage Determination Vote</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not Covered</td>
</tr>
<tr>
<td>Proton Beam Therapy</td>
</tr>
</tbody>
</table>

Discussion:

The committee determined a vote of **coverage with conditions** for Proton Beam Therapy. The committee identified specific conditions for coverage for ocular cancer, pediatric cancers and central nervous system cancer. Additionally, they determined to cover other non-metastatic cancers at state agency discretion when a patient has had prior radiation in the expected treatment field and other forms of therapy are contraindicated. The committee determined all other conditions to be not covered for treatment with Proton Beam Therapy.

Draft Limitations of Coverage:

Proton Beam Therapy is a **covered benefit with conditions** for:

- Ocular tumors
- Pediatric cancers (e.g., medulloblastoma, retinoblastoma, Ewing’s sarcoma)
- Central nervous system tumors (e.g., brain, spinal and paraspinal tumors)
- Other non-metastatic cancers with the following conditions:
Patient has had prior radiation in the expected treatment field with contraindication to all other forms of therapy, and

At agency discretion.

**Non-Covered Indicators:**

Proton Beam Therapy is not covered for all other conditions.

**Action**

The committee checked for availability of a Medicare coverage decision. CMS does not have a national coverage determination (NCD) for Proton Beam Therapy, but does have a local coverage determination (LCD).

The committee reviewed selected clinical guidelines from the National Comprehensive Cancer Network, American Society for Radiation Oncology, American College of Radiology, American Cancer Society and Alberta Health Services. The committee also reviewed training standards published by the American College of Radiology and joint publications with the American Society for Radiation Oncology and the American Association of Physicists in Medicine.

The committee Chair directed HTA staff to prepare a Draft Findings and Decision document on Proton Beam Therapy reflective of the majority vote for final approval at the next public meeting.

6. **Draft Key Questions:**

The Chair directed members to review draft key questions proposed for technical assessment of Functional Neuroimaging for Primary Degenerative Dementia or Mild Cognitive Impairment and Screening & Monitoring Tests for Osteopenia/ Osteoporosis.

The Chair called for further comments. No further comment on the draft key questions.

7. Meeting adjourned.